DJIA 16,399.67 19.26 0.12%
NASDAQ 4,316.07 57.64 1.35%
S&P 500 1,904.01 17.25 0.91%
market minute promo

MannKind Corp (NASDAQ: MNKD)

5.36 -0.33 (-5.80%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

MNKD $5.36 -5.80%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $5.62
Previous Close $5.69
Daily Range $5.21 - $5.79
52-Week Range $3.80 - $11.48
Market Cap $2.2B
P/E Ratio -8.62
Dividend (Yield) $0.00 (0.0%)
Volume 6,615,252
Average Daily Volume 6,310,289
Current FY EPS -$0.33

Sector

Healthcare

Industry

Drugs

MannKind Corp (MNKD) Description

A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer. Website: http://www.mannkindcorp.com/

News & Commentary

Why Is Sanofi Betting on MannKind Corporation's Afrezza?

Sanofi's global dominance over the lucrative diabetes market is facing a serious challenge with the patent expiration of Lantus, the most commonly prescribed insulin in the world. Can MannKind's inhaled insulin product help Sanofi retain its edge?

Goldman Sachs Analyst Neutral Rating of MannKind Feels Like Downgrade

MannKind: 5 Potential Technosphere Applications

Discovery Laboratories: Collaboration With Battelle Is Validation Of Aerosurf's Potential By A Sophi

Discovery Laboratories: Collaboration With Battelle Is Validation Of Aerosurf's Potential By A Sophisticated Third Party

Biotech Stock Mailbag: Small-Cap Rebound, Avanir, Ohr, CytoSorbents

MannKind (MNKD) Worth Watching: Stock Gains 12.9% - Tale of the Tape

Dance until the music stops: Insulin biotech Dance Biopharm withdraws $75 million IPO

The State Of MannKind

MannKind: Technosphere Is The Real Game Changer

MNKD January 2017 Options Begin Trading

Short Interest in Biotech Becomes Company Specific

See More MNKD News...

MNKD's Top Competitors

MNKD $5.36 (-5.80%)
Current stock: MNKD
AMGN $137.51 (2.86%)
Current stock: AMGN
GILD $102.21 (1.45%)
Current stock: GILD
BIIB $311.41 (1.53%)
Current stock: BIIB